ADC Therapeutics to Participate in March Investor Conferences
MWN-AI** Summary
ADC Therapeutics SA (NYSE: ADCT), a leader in the development of antibody-drug conjugates (ADCs), has announced its participation in key investor conferences scheduled for March 2026. Notably, the company will present at the TD Cowen 46th Annual Health Care Conference on March 3, where CEO Ameet Mallik will discuss the company’s strategic directions and advancements in their portfolio, including their flagship product ZYNLONTA (loncastuximab tesirine-lpyl). This presentation will take place in Boston at 11:50 a.m. EST, and a webcast will be available for those unable to attend in person.
Additionally, ADC Therapeutics will engage in one-on-one meetings at the Jefferies Biotech on the Beach Summit on March 11 in Miami. This format allows for more personalized interactions with potential investors and analysts, providing insight into the company’s operations and growth trajectory. Webcast details will also be accessible through the company’s investor relations website, ensuring broad accessibility to these discussions.
Headquartered in Lausanne, Switzerland, ADC Therapeutics is focused on transforming cancer treatment with innovative ADCs, particularly in hematological malignancies. ZYNLONTA has gained FDA accelerated approval and conditional endorsement from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma. The company continues development for various line therapies and in combination with other agents, positioning it at the forefront of oncology innovations.
As ADC Therapeutics moves forward, the upcoming investor engagements will be pivotal in communicating its growth strategy and recent developments, particularly as the company navigates through various clinical trials and regulatory processes that could significantly impact its market position. For detailed updates, investors are encouraged to follow the company’s communications and assess the risks highlighted in their forward-looking statements.
MWN-AI** Analysis
ADC Therapeutics (NYSE: ADCT) is poised for significant investor engagement through its participation in key conferences this March, including the TD Cowen 46th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit. This visibility presents an excellent opportunity for investors to gauge the company’s trajectory and future prospects.
As a commercial-stage leader in the antibody drug conjugates (ADC) segment, ADC Therapeutics is driving innovation, particularly with its FDA-approved product ZYNLONTA, which targets relapsed or refractory diffuse large B-cell lymphoma. The successful commercialization and ongoing developments of ZYNLONTA, along with other compounds in its portfolio, are crucial discussion points that investors should focus on. Ameet Mallik, the CEO, will articulate the company’s strategic vision and upcoming milestones, providing insights that could influence investor sentiment.
Investors must pay close attention to ADC Therapeutics’ clinical trial results scheduled for announcement later this year, particularly for the LOTIS-7 trial and the anticipated data from LOTIS-5. The outcomes of these trials are indicators not only of ADC’s product efficacy but also of potential revenue trajectories. Further, the company must navigate its debt obligations and operational challenges, which could influence its growth strategy and cash flow sustainability.
Overall, ADC Therapeutics presents an intriguing investment proposition due to its innovative product offerings and the potential for growth in the burgeoning ADC market. Investors should utilize the insights gained from the upcoming conferences to make informed decisions, keeping an eye on critical trial results and market conditions that could impact the stock's performance. Given the complexities in the healthcare sector, a cautious yet optimistic approach would be advisable in evaluating ADCT as part of a diversified portfolio.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in upcoming investor conferences in March:
TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Presentation Time: 11:50 a.m. EST
Format: Corporate presentation
Speaker: Ameet Mallik, Chief Executive Officer
Location: Boston, MA
To register for the webcast, click here.
Jefferies Biotech on the Beach Summit
Date: March 11, 2026
Format: One-on-one meetings
Location: Miami, FL
A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com with a replay available for approximately 30 days following.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).
ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: changes to the preliminary unaudited Q4 and full year 2025 net product revenue and cash and cash equivalents as of December 31, 2025; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
SOURCE ADC Therapeutics SA
FAQ**
How does ADC Therapeutics SA ADCT plan to leverage the accelerated approval of ZYNLONTA to expand its market share in the treatment of diffuse large B-cell lymphoma during the upcoming investor conferences?
With several clinical trials underway, what key updates can investors expect regarding the LOTIS-5 and LOTIS-7 studies from ADC Therapeutics SA ADCT during the March conferences?
ADC Therapeutics SA ADCT has a strong focus on innovation in ADC development; can you elaborate on any new partnerships or collaborations that may enhance your clinical pipeline shared at the upcoming conferences?
Considering ADC Therapeutics SA ADCT’s goal to ensure a cash runway until at least 2028, how will you address any challenges regarding financial stability and regulatory compliance during the presentations at the March investor conferences?
**MWN-AI FAQ is based on asking OpenAI questions about ADC Therapeutics SA (NYSE: ADCT).
NASDAQ: ADCT
ADCT Trading
1.26% G/L:
$4.825 Last:
528,453 Volume:
$4.74 Open:
